BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26953564)

  • 1. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.
    Roberts DR; Lindhorst SM; Welsh CT; Maravilla KR; Herring MN; Braun KA; Thiers BH; Davis WC
    Invest Radiol; 2016 May; 51(5):280-9. PubMed ID: 26953564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis.
    Birka M; Wentker KS; Lusmöller E; Arheilger B; Wehe CA; Sperling M; Stadler R; Karst U
    Anal Chem; 2015 Mar; 87(6):3321-8. PubMed ID: 25708271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
    Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
    Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
    Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
    Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
    McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Murray DL; Thielen KR; Williamson EE; Eckel LJ
    Radiology; 2015 Jun; 275(3):772-82. PubMed ID: 25742194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
    Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
    Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
    Murata N; Gonzalez-Cuyar LF; Murata K; Fligner C; Dills R; Hippe D; Maravilla KR
    Invest Radiol; 2016 Jul; 51(7):447-53. PubMed ID: 26863577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
    Layne KA; Dargan PI; Archer JRH; Wood DM
    Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.
    Stanescu AL; Shaw DW; Murata N; Murata K; Rutledge JC; Maloney E; Maravilla KR
    Pediatr Radiol; 2020 Mar; 50(3):388-396. PubMed ID: 31989188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents.
    Pietsch H; Lengsfeld P; Jost G; Frenzel T; Hütter J; Sieber MA
    Eur Radiol; 2009 Jun; 19(6):1417-24. PubMed ID: 19169690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities.
    McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Paolini MA; Murray DL; Williamson EE; Eckel LJ
    Radiology; 2017 Nov; 285(2):546-554. PubMed ID: 28653860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.
    Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS
    Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain gadolinium deposition after administration of gadolinium-based contrast agents.
    Kanda T; Oba H; Toyoda K; Kitajima K; Furui S
    Jpn J Radiol; 2016 Jan; 34(1):3-9. PubMed ID: 26608061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats.
    Bussi S; Coppo A; Botteron C; Fraimbault V; Fanizzi A; De Laurentiis E; Colombo Serra S; Kirchin MA; Tedoldi F; Maisano F
    J Magn Reson Imaging; 2018 Mar; 47(3):746-752. PubMed ID: 28730643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses: Current Status of Preclinical and Clinical Studies.
    Parillo M; Mallio CA; Van der Molen AJ; Rovira À; Ramalho J; Ramalho M; Gianolio E; Karst U; Radbruch A; Stroomberg G; Clement O; Dekkers IA; Nederveen AJ; Quattrocchi CC;
    Invest Radiol; 2023 Aug; 58(8):530-538. PubMed ID: 37185158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents.
    Richter H; Bücker P; Martin LF; Dunker C; Fingerhut S; Xia A; Karol A; Sperling M; Karst U; Radbruch A; Jeibmann A
    Radiology; 2021 Dec; 301(3):637-642. PubMed ID: 34546128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.